Voiant is the industry leading AI-based clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. Voiant combines leadership in artificial intelligence and visionary computing, key opinion leaders for strategic therapeutic areas alignment, and clinical research experts to deliver operational excellence and consistent execution – providing the shortest path to the highest quality imaging data for clinical trials. Voiant has interpreted +1 billion images from over 700 global clinical trials, aiding numerous biopharmaceutical companies bringing new treatments to patients across oncology, respiratory, ophthalmology, cardiovascular, gastrointestinal, and liver disease domains. Voiant Hub is our built for purpose AI-powered platform, enabling us to manage the entire clinical imaging process while providing site management, as well as full transparency to sponsors every step of the way from image upload, quality control, read & analysis to delivering high quality clinical imaging endpoints.
Thirona
Thirona provides advanced lung image analysis with artificial intelligence through expertise-based services for MedTech, pharmaceutical and CRO companies. Thirona’s lung quantification platform LungQ® consists of a comprehensive portfolio of robust high-performance algorithms trained on a wide range of disease-specific datasets, offering market-leading AI analytical capabilities, with consistent and reproducible results. Integrated in multiple certified clinical end-products, our software is used by clinicians in more than 600 hospitals worldwide.
TechnoPulm Ltd.
TechnoPulm introduces STS, the future of pulmonary diagnostics. STS is FDA-cleared and is the first handheld device to deliver complete pulmonary function testing (PFT) in just 30 seconds, replacing bulky hospital equipment with a compact, all-in-one solution. Integrating cabinless plethysmography, spirometry, CO₂/FeNO, and diffusion testing, STS provides instant, clinical-grade results at the point of care or even at home. This groundbreaking technology eliminates hospital dependency, expands access to advanced diagnostics, and empowers pulmonologists, general practitioners, primary care physicians, and specialists. STS enables early detection and monitoring of asthma, COPD, pulmonary fibrosis, and other respiratory conditions.